Altimmune Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Did you know?
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedProfile
Valuation (TTM)
Market Cap$294.00M
P/E-3.34
EV—
P/B1.31
Shares Out104.25M
P/Sales8166.58
Revenue$36000.00
EV/EBITDA—
Altimmune Inc (ALT) Stock Analysis
Market Cap$294.00M
Current Price$2.82
P/E Ratio-3.34
Forward P/E—
PEG Ratio0.16
EPS$-1.00
Book Value$2.16
P/B Ratio1.31
ALT Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 10M
Revenue
6M
FY19
8M
FY20
4M
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
ALT 52-Week Range
$2.60
$7.71
50-Day MA: $3.49200-Day MA: $4.03
Did you know?
Trading 100% above its estimated fair value of $0.00.
Altimmune Inc (ALT) Financial Summary
Altimmune Inc (ALT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $2.82 with a market capitalization of $294.00M.
Key valuation metrics include a P/E ratio of -3.34, price-to-book ratio of 1.31, and EPS of $-1.00. The company reports a profit margin of -244702.8% and return on equity of -39.2%.
ALT Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $294.00M |
| P/E Ratio | -3.34 |
| EPS | $-1.00 |
| P/B Ratio | 1.31 |
| P/S Ratio | 8166.58 |
| Profit Margin | -244702.8% |
| Return on Equity | -39.2% |
| Debt/Equity | 0.15 |
ALT Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $5.80M | $-20.52M |
| FY20 | $8.19M | $-49.04M |
| FY21 | $4.41M | $-97.09M |
| FY22 | $-68000.00 | $-84.71M |
| FY23 | $426000.00 | $-88.45M |
| FY24 | $20000.00 | $-95.06M |
| FY25 | $41000.00 | $-88.09M |
Altimmune Inc (ALT) Valuation
Based on GoodMoat's DCF model, Altimmune Inc has a fair value estimate of $0.00. At the current price of $2.82, the stock appears 162817.4% overvalued relative to our intrinsic value estimate.
ALT Quality Indicators
Altimmune Inc maintains a profit margin of -244702.8% and an operating margin of -230461.0%. Return on equity stands at -39.2%. The current ratio is 18.55. Debt-to-equity ratio is 0.15.
About Altimmune Inc
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
ALT Free Cash Flow
Altimmune Inc generated $-67.55M in trailing twelve-month free cash flow, representing an FCF yield of -22.98%. This low FCF yield may reflect heavy reinvestment or growth spending.
ALT Shares Outstanding
Altimmune Inc has 0.10 billion shares outstanding at a share price of $2.82, giving it a market capitalization of $294.00M.